Dark

Check out our Dark Pool Levels

DRRX
Durect Corp
stock NASDAQ

Inactive

Sep 10, 2025

1.91USD-1.036%(-0.02)2,787,659

Pre-market

0.00USD-100.000%(-1.93)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 6, 2022

04:06PM EST DURECT Corporation to Participate in H.C. Wainwright Bioconnect Conference PR Newswire

Dec 22, 2021

07:33AM EST DURECT, Innocoll Announce $136 Mln U.S. Licensing Agreement For POSIMIR RTTNews

07:31AM EST DURECT And Innocoll Announce $136M US Licensing Agreement For POSIMIR (Bupivacaine Solution); Innocoll To Make Near-Term Payments To DURECT Of $6M With Potential For $130M In Milestones Benzinga

07:31AM EST DURECT and Innocoll Announce a $136 Million U.S. Licensing Agreement for PR Newswire

Dec 14, 2021

09:01AM EST DURECT Corporation Expands Board of Directors with Appointment of PR Newswire

Nov 29, 2021

09:02AM EST DURECT Corporation to Participate in Alcoholic Liver Disease Workshop Today at PR Newswire

Nov 12, 2021

09:09AM EST Data Says Presentation Today At The Liver Meeting 2021 Shows Increasing Hospital Admissions For Alcohol-Associated Hepatitis (AH) In The U.S. Benzinga

09:02AM EST Data Presentation Today at The Liver Meeting(r) 2021 Shows Increasing Hospital PR Newswire

Nov 10, 2021

09:15AM EST DURECT Corporation Doses First Ex-U.S. Patient In Phase 2b AHFIRM Study Of Larsucosterol (DUR-928) In Severe Alcohol-Associated Hepatitis Benzinga

09:04AM EST DURECT Doses First Ex-U.S. Patient In Phase 2b Study Of Larsucosterol In Severe Alcohol-Associated Hepatitis RTTNews

09:01AM EST DURECT Corporation Doses First ex-U.S. Patient in Phase 2b AHFIRM Study of PR Newswire

Nov 8, 2021

09:02AM EST Hospitalized Alcohol-Associated Hepatitis (AH) Patients in the U.S. to be Presented at The Liver Meeting(r) 2021 PR Newswire

Nov 2, 2021

04:57PM EDT Durect Q3 EPS $(0.04) Beats $(0.05) Estimate, Sales $2.17M Beat $1.95M Estimate Benzinga

04:06PM EDT DURECT Corporation Reports Third Quarter 2021 Financial Results and Update of PR Newswire

10:41AM EDT Earnings Scheduled For November 2, 2021 Benzinga

Oct 26, 2021

09:02AM EDT DURECT Corporation to Announce Third Quarter 2021 Financial Results and Provide PR Newswire

Oct 7, 2021

09:05AM EDT DURECT Corporation Fireside Chat at the H.C. Wainwright 5th Annual NASH PR Newswire

08:24AM EDT The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results Benzinga

Oct 6, 2021

07:33AM EDT The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal Benzinga

Sep 23, 2021

09:14AM EDT DURECT Corporation To participate In Fireside Chat At Cantor Fitzgerald Global Healthcare Conference 2021 Sept. 28 Benzinga

09:04AM EDT DURECT Corporation Fireside Chat at the Cantor Fitzgerald Global Healthcare PR Newswire

Sep 15, 2021

09:03AM EDT DURECT Corporation Fireside Chat at Oppenheimer's Fall Healthcare Life Sciences PR Newswire

Sep 7, 2021

09:12AM EDT DURECT Corporation Fireside Chat at the H.C. Wainwright Annual Global PR Newswire

Aug 18, 2021

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

Aug 17, 2021

08:28AM EDT The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business Benzinga

Jul 29, 2021

04:40PM EDT Durect Q2 EPS $(0.04), Inline, Sales $2.30M Miss $3.65M Estimate Benzinga

04:06PM EDT DURECT Corporation Announces Second Quarter 2021 Financial Results and Update PR Newswire

04:23AM EDT Earnings Scheduled For July 29, 2021 Benzinga

Jul 22, 2021

08:31AM EDT DURECT Corporation to Announce Second Quarter 2021 Financial Results and PR Newswire

Jul 20, 2021

08:20AM EDT The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street Benzinga

Jul 16, 2021

07:37AM EDT The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study Benzinga

Jul 15, 2021

08:08AM EDT The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs Benzinga

Jul 14, 2021

04:31PM EDT DURECT Corporation to Present at the 2021 Epigenetic Therapeutic Targets PR Newswire

07:48AM EDT The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues Benzinga

Jul 9, 2021

07:36AM EDT The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO Benzinga

Jul 7, 2021

07:41AM EDT The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend Benzinga

Jun 23, 2021

09:10AM EDT DURECT Presents Addl Clinical Data From DUR-928 Phase 1b Trial In NASH And Phase 1 Trial In Hepatic Impairment RTTNews

09:03AM EDT Trial in NASH and Phase 1 Trial in Hepatic Impairment at the International Liver Conference 2021 (EASL) PR Newswire

09:03AM EDT DURECT Highlights Presentation Of Added Clinical Data From DUR-928 Phase 1b Trial In NASH, Phase 1 Trial In Hepatic Impairment At Int'l. Liver Conference Jun. 23-26 Benzinga

Jun 9, 2021

09:22AM EDT DURECT Will Present Added Clinical Data From DUR-928 Studies In NASH, In Hepatic Impairment At Upcoming Int'l. Live Conference Benzinga

09:14AM EDT DURECT To Present Additional Clinical Data From DUR-928 Studies In NASH And In Hepatic Impairment RTTNews

09:03AM EDT NASH (Phase 1b) and in Hepatic Impairment (Phase 1) at Upcoming International Liver Conference 2021 (EASL) PR Newswire

May 5, 2021

06:33AM EDT HC Wainwright & Co. Reiterates Buy on Durect, Announces $6 Price Target Benzinga

May 4, 2021

05:26PM EDT Durect: Q1 Earnings Insights Benzinga

04:43PM EDT Durect Q1 EPS $(0.05) Misses $(0.04) Estimate, Sales $2.20M Miss $3.00M Estimate Benzinga

04:06PM EDT DURECT Corporation Announces First Quarter 2021 Financial Results and Update of PR Newswire

08:10AM EDT The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data Benzinga

Apr 27, 2021

08:31AM EDT DURECT Corporation to Announce First Quarter 2021 Financial Results and Provide PR Newswire

Mar 9, 2021

09:04AM EST DURECT Corporation Announces Publication of DUR-928's Mechanism of Action PR Newswire

Mar 4, 2021

05:31PM EST Durect: Q4 Earnings Insights Benzinga

04:11PM EST Durect Q4 EPS $0.02 Beats $(0.03) Estimate, Sales $2.21M Miss $6.57M Estimate Benzinga

04:07PM EST DURECT Corp. Q4 EPS $0.02 Vs. Loss $0.02 Year Ago RTTNews

04:06PM EST DURECT Corporation Announces Fourth Quarter and Full Year 2020 Financial PR Newswire

04:07AM EST Earnings Scheduled For March 4, 2021 Benzinga

Mar 3, 2021

06:03PM EST DURECT Corporation to Participate in Three Investor Conferences in March 2021 PR Newswire

Feb 25, 2021

04:25PM EST DURECT Corporation to Announce 2020 Financial Results and Provide Business PR Newswire

Feb 4, 2021

09:21AM EST DURECT Corporation Announces Pricing of $42.5 Million Public Offering of Common PR Newswire

09:21AM EST DURECT Corp. Pricing Of $42.5 Mln Public Offering Of Common Stock RTTNews

09:21AM EST DURECT Corporation Announces Pricing Of $42.5M Public Offering Of 17.708M Shares Benzinga

07:22AM EST The Daily Biotech Pulse: Novartis COVID-19 Drug Readout, Merck And Roche Earnings, 3 IPOs Benzinga

Feb 3, 2021

04:03PM EST DURECT Reports Common Stock Offering, No Size Disclosed Benzinga

04:02PM EST DURECT Corporation Announces Proposed Offering of Common Stock PR Newswire

08:17AM EST Chardan Capital Maintains Buy on Durect, Raises Price Target to $8 Benzinga

Feb 2, 2021

09:43AM EST DURECT Shares Soar After FDA Nod For Post-Surgical Pain Medication Posimir Benzinga

08:14AM EST DURECT Says FDA Has Approved POSIMIR For Infiltration Use RTTNews

08:05AM EST DURECT Corporation Announces FDA Approval Of POSIMIR For Post-Surgical Pain Reduction For Up To 72 Hours Following Arthroscopic Subacromial Decompression Benzinga

08:03AM EST Pain Reduction for up to 72 Hours Following Arthroscopic Subacromial Decompression PR Newswire

Jan 25, 2021

08:54AM EST DURECT Says First Patient Dosed In Phase 2b AHFIRM Study Of DUR-928 In Severe Alcohol-Associated Hepatitis RTTNews

08:33AM EST DURECT Corporation Announces First Patient Dosed In Phase 2b AHFIRM Study Of DUR-928 In Severe Alcohol-Associated Hepatitis Benzinga

08:31AM EST DURECT Corporation Announces First Patient Dosed in Phase 2b AHFIRM Study of PR Newswire

Jan 5, 2021

08:31AM EST DURECT Corporation Appoints Two New Board Members PR Newswire

Jan 4, 2021

08:58AM EST DURECT Announces Closing Of LACTEL Absorbable Polymer Product Line Sale To Evonik And Receipt Of $15 Mln RTTNews

08:33AM EST DURECT Corporation Announces Closing Of LACTEL Absorbable Polymer Product Line Sale To Evonik And Receipt Of $15M Benzinga

08:31AM EST DURECT Corporation Announces Closing of LACTEL(r) Absorbable Polymer Product PR Newswire

Dec 21, 2020

08:31AM EST DURECT Corporation to Participate in Investor Conferences in January 2021 PR Newswire

Dec 16, 2020

11:36AM EST Durect shares were trading higher after the company announced that its DUR-928 eas granted FDA Fast Track Designation for the treatment of alcoholic hepatitis. Benzinga

08:34AM EST DURECT Says FDA Granted Fast Track Designation To DUR-928 For Treatment Of Alcoholic Hepatitis RTTNews

08:31AM EST DURECT Corporation Announces DUR-928 Granted FDA Fast Track Designation For Treatment Of Alcoholic Hepatitis Benzinga

08:31AM EST DURECT Corporation Announces DUR-928 Granted FDA Fast Track Designation for PR Newswire

Dec 7, 2020

11:15AM EST DURECT Corporation to Sell its LACTEL(r) Absorbable Polymer Product Line to PR Newswire

11:15AM EST DURECT Corporation To Sell Its LACTEL Absorbable Polymer Product Line To Evonik For $15M Benzinga

Nov 13, 2020

09:09AM EST DURECT Announces Addl Safety Data And Efficacy Signals From Phase 1b Clinical Trial Of DUR-928 In NASH Patients RTTNews

09:02AM EST DURECT Reports Added Safety Data, Efficacy Signals From Phase 1b Trial Of DUR-928 In NASH Patients At The Liver Meeting Digital Benzinga

09:01AM EST Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience(tm) 2020 PR Newswire

07:40AM EST The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations Benzinga

Nov 10, 2020

08:31AM EST DURECT Corporation to Host Webinar on the Treatment of Alcoholic Hepatitis PR Newswire

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Nov 2, 2020

04:11PM EST Durect Q3 EPS $(0.05) Misses $(0.04) Estimate, Sales $2.70M Miss $3.56M Estimate Benzinga

04:06PM EST DURECT Corporation Announces Third Quarter 2020 Financial Results and Update of PR Newswire

04:02PM EST DURECT Corporation Appoints Dr. Norman Sussman as Chief Medical Officer PR Newswire

07:55AM EST Earnings Scheduled For November 2, 2020 Benzinga

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 30, 2020

10:06AM EDT Benzinga's Top Upgrades, Downgrades For October 30, 2020 Benzinga

05:08AM EDT Chardan Capital Initiates Coverage On Durect with Buy Rating, Announces Price Target of $7 Benzinga

Oct 27, 2020

08:31AM EDT DURECT Corporation to Announce Third Quarter 2020 Financial Results and Provide PR Newswire

Oct 26, 2020

04:31PM EDT DURECT Corporation To Participate In ROTH Capital Partners Healthcare Event 'Covid-19 Therapeutics in Development' Oct. 28 Benzinga

04:30PM EDT DURECT Corporation to Participate in the ROTH Capital Partners Healthcare Event PR Newswire

Oct 12, 2020

09:45AM EDT Roth Capital Initiates Coverage On Durect with Buy Rating, Announces Price Target of $7 Benzinga

Oct 5, 2020

08:32AM EDT DURECT Corporation To Present Additional Safety And Efficacy Signals From Phase 1b Clinical Trial Of DUR-928 In NASH Patients At The Liver Meeting Digital Experience 2020 Nov. 13-16 Benzinga

08:31AM EDT 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience(tm) 2020 PR Newswire

Sep 30, 2020

04:54PM EDT DURECT Corporation to Participate in Fireside Chat at H.C. Wainwright 4th PR Newswire

Sep 23, 2020

08:37AM EDT DURECT: First Patient Dosed In Phase 2 Study Of DUR-928 In COVID-19 Patients With Acute Liver Or Kidney Injury RTTNews

08:31AM EDT DURECT Corporation Announces First Patient Dosed In Phase 2 Safety And Efficacy Study Of DUR-928 In COVID-19 Patients With Acute Liver Or Kidney Injury Benzinga

08:31AM EDT DURECT Corporation Announces First Patient Dosed in Phase 2 Safety and Efficacy PR Newswire

Sep 22, 2020

08:37AM EDT DURECT Corporation Announces Design Of Phase 2b AHFIRM AH Study Benzinga

08:35AM EDT DURECT Announces Study Design For Phase 2b AHFIRM Clinical Trial Of DUR-928 In Severe AH Patients RTTNews

08:31AM EDT DURECT Corporation Announces Design of Phase 2b AH Study (AHFIRM) PR Newswire

Sep 10, 2020

08:31AM EDT DURECT Corporation to Participate in September Virtual Investor Conferences PR Newswire

Aug 27, 2020

08:36AM EDT DURECT Announces Presentation Of Phase 2a Pharmacokinetic Data Of DUR-928 In Alcoholic Hepatitis RTTNews

08:31AM EDT DURECT Corporation Announces Presentation of Phase 2a Pharmacokinetic Data of PR Newswire

Aug 26, 2020

04:31PM EDT DURECT Corporation Fireside Chat hosted by Ellie Merle of Cantor Fitzgerald PR Newswire

Aug 5, 2020

08:31AM EDT DURECT to Present at the BTIG Biotechnology Conference 2020 PR Newswire

Aug 4, 2020

09:50AM EDT Durect shares are trading higher after the company reported on Monday Q2 EPS of $0.07, up from $(0.04) year over year and better-than-expected Q2 sales results. UPDATE: Shares have since reversed, now lower. Benzinga

Aug 3, 2020

04:11PM EDT Durect Q2 EPS $0.07 Up From $(0.04) YoY, Sales $25.84M Beat $11.48M Estimate Benzinga

04:06PM EDT DURECT Corporation Announces Second Quarter 2020 Financial Results and Update PR Newswire

04:13AM EDT Earnings Scheduled For August 3, 2020 Benzinga

Jul 31, 2020

12:56PM EDT Oppenheimer Initiates Coverage On Durect with Outperform Rating, Announces Price Target of $7 Benzinga

Jul 30, 2020

05:20PM EDT Hearing Oppenheimer Initiated Coverage On Durect Corp With An Outperform Rating, $7 Price Target Benzinga

Jul 28, 2020

08:31AM EDT DURECT Corporation to Announce Second Quarter 2020 Financial Results and PR Newswire

Share